+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Global Insulin Pen Market, by Product Type, by Distribution Channel, by Application, by Region ; Trend Analysis, Competitive Market Share & Forecast, 2016-26

  • ID: 5024911
  • Report
  • April 2020
  • Region: Global
  • 186 pages
  • Blueweave Consulting & Research Pvt Ltd
1 of 4


  • Berlin-Chemie Ag
  • Biocon
  • Companion Medical
  • Eli Lilly and Company
  • Novo Nordisk A/S
  • Owen Mumford Ltd.
  • MORE
Insulin is necessary for the management of type 1 diabetes and is more commonly used for the medication of type 2 diabetes. The insulin pen was first launched over 20 years ago and has evolved to provide significant working advantages compared with the syringe and vial. Insulin Pen devices are now used by patients with diabetes globally, but there are marked geographic differences in the use of reusable and disposable pens. In many countries, syringe and vial are still the most popular method of delivering insulin, whereas, in many countries, the use of reusable or disposable pens is more common. Diabetes is an endocrine health problem that causes high levels of sugar in the blood. For diabetic patients, blood sugar must be monitored carefully using a glucometer. If insulin is necessary to be injected in order to regulate the activity of the pancreas, this can be accomplished using insulin injection pens, either pre-filled disposable or refillable. This allows for light and easy use while providing accurate information on the dose. These factors are expected to propel the insulin pen market growth during the forecast period.

An electronic insulin pen was designed for diabetic patient’s dependent on insulin use in order to prevent wrong timing and wrong dosage caused by old age, vision, or mental illness. The insulin pen can be used electronically for routine dose injections and was designed to be able to used manually in the emergency. It is aimed that the patient can set the dose easily by using the fairly simple menu of the device. Additionally, the device was not designed as disposable, and the device was designed as reusable by changing the insulin tube. Because the tube chamber was designed to be suitable for all types of insulin, it can be used by changing the tube without using a different pen. Dose accuracy was adjusted with a low error by performing insulin dose measurements on a sensitive balance.

Increasing prevalence of diabetes is expected to drive the global insulin pen market

Diabetes is a metabolic disorder in both the developed and developing countries. It is expected that about 371 million people have disease worldwide and this number has been estimated to rise up to 552 million by 2030. The rate of prevalence of diabetes is high in Asian countries. About 92.3 and 63 million people in China and India suffer from this metabolic disorder respectively. Diabetes (T2D) reduces the life expectancy by 5–10 years. Prevalence of diabetes is rapidly increasing worldwide due to interactions between environmental factors, genetic factors and lifestyle. Furthermore, factors such as population growth, urbanization, aging, and increasing prevalence of obesity and physical inactivity are significantly contributing to the increasing global burden of diabetics. This is the major growth driver for the global insulin pen market.

Ease of use is expected to the drive the market growth of global insulin pen market

The insulin pen offers better convenience, flexibility, and quality of life results with pen devices as compared to the conventional insulin delivery devices.6 Dose accuracy with insulin pens was also reported to be better in many studies in comparison to vials and syringes method, especially at low doses (≤5 IU). All these factors are essential in improving patient adherence to the treatment and also reducing hypoglycemic episodes.

Reusable Insulin pen segment is expected to dominate the market during the forecast period

With individual use of the pen device, the prospect of infection is decreased. Examples of such reusable insulin pens are Humapen® (for both human and analog insulins), NovoPen® 3 (for both human and analog insulins), Autopen® pen, Optipen®, and Wosulin pen. HumaPen® MEMOIR(TM) comes with a memory allowing diabetes patients, especially those on multiple mealtime doses, to record and examine their last 16 insulin doses. Insulin pens have shown dose accuracy before and after simulation of 5 years of use across a broad range of temperature and humidity conditions and after mechanical challenges.

These factor help the global insulin market growth during the forecast period.

North America expected to witness significant growth in the market during the forecast period

Insulin medication is deemed to be the center for the treatment of people who have diabetes, and in the United States, the adoption of insulin pens is increasing significantly as compared to the needles and syringes during the forecast period.

Asia-Pacific is also estimated to grow at a high CAGR during the forecast period due to the high population in China, India, and other Asian countries.

Products will be dispatched within 48 hours.
Note: Product cover images may vary from those shown
2 of 4


  • Berlin-Chemie Ag
  • Biocon
  • Companion Medical
  • Eli Lilly and Company
  • Novo Nordisk A/S
  • Owen Mumford Ltd.
  • MORE
1. Research Framework
1.1. Research Objective
1.2. Product Overview
1.3. Market Segmentation

2. Research Methodology
2.1. Qualitative Research
2.1.1. Primary & Secondary Sources
2.2. Quantitative Research
2.2.1. Primary & Secondary Sources
2.3. Breakdown of Primary Research Respondents, By Region
2.3.1. Secondary Research
2.3.2. Primary Research
2.4. Breakdown of Primary Research Respondents
2.5. Market Size Estimation
2.6. Assumption for the Study
2.7. Market Breakdown & Data Triangulation

3. Executive Summary

4. Global Insulin Pen Industry Insights
4.1. Industry Value Chain Analysis
4.2. DROC Analysis
4.2.1. Growth Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Technological Landscape/Recent Development
4.4. Company Market Share Analysis, 2019
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Intensity of Rivalry

5. Global Insulin Pen Market Overview
5.1. Market Size & Forecast by Value, 2016-2026
5.1.1. By Value (USD Billion)
5.2. Market Share & Forecast
5.2.1. By Product Type Disposable Reusable
5.2.2. By Distribution Channel Online Pharmacies Hospital Pharmacies Retail Pharmacies Diabetes Clinics
5.2.3. By Application Type 1 Diabetes Type 2 Diabetes
5.2.4. By Region North America Europe Asia Pacific Latin America Middle East & Africa

6. North America Insulin Pen Market
6.1. Market Size & Forecast by Value, 2016-2026
6.1.1. By Value (USD Billion)
6.2. Market Share & Forecast
6.2.1. By Product Type
6.2.2. By Distribution Channel
6.2.3. By Application
6.2.4. By Country United States Canada

7. Europe Insulin Pen Market
7.1. Market Size & Forecast by Value, 2016-2026
7.1.1. By Value (USD Billion)
7.2. Market Share & Forecast
7.2.1. By Product Type
7.2.2. By Distribution Channel
7.2.3. By Application
7.2.4. By Country Germany United Kingdom France Italy Spain Rest of Europe

8. Asia Pacific Insulin Pen Market
8.1. Market Size & Forecast by Value, 2016-2026
8.1.1. By Value (USD Billion)
8.2. Market Share & Forecast
8.2.1. By Product Type
8.2.2. By Distribution Channel
8.2.3. By Application
8.2.4. By Country China India Japan Rest of Asia Pacific

9. Latin America Insulin Pen Market
9.1. Market Size & Forecast by Value, 2016-2026
9.1.1. By Value (USD Billion)
9.2. Market Share & Forecast
9.2.1. By Product Type
9.2.2. By Distribution Channel
9.2.3. By Application
9.2.4. By Country Brazil Mexico Argentina Rest of Latin America

10. Middle East & Africa Insulin Pen Market
10.1. Market Size & Forecast by Value, 2016-2026
10.1.1. By Value (USD Billion)
10.2. Market Share & Forecast
10.2.1. By Product Type
10.2.2. By Distribution Channel
10.2.3. By Application
10.2.4. By Country Saudi Arabia UAE South Africa Rest of Middle East & Africa

11. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) *
11.1. B. Braun Melsungen AG
11.2. Eli Lilly and Company
11.3. Artsana S.p.A.
11.4. Novo Nordisk A/S
11.5. Owen Mumford Ltd.
11.7. HTL-Strefa
11.8. Companion Medical
11.9. Berlin-Chemie Ag
11.10. Pendiq Gmbh
11.11. Emperra GmbH E-Health Technologies
11.12. Ypsomed Ag
11.13. Sanofi
11.14. Digital Medics
11.15. Diamesco
11.16. Gerresheimer AG
11.17. Companion Medical
11.18. Biocon
11.19. Jiangsu Delfu medical device Co.
11.20. Lantus
11.21. Other prominent players
Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • Owen Mumford Ltd.
  • Novo Nordisk A/S
  • Companion Medical
  • Berlin-Chemie Ag
  • Pendiq Gmbh
  • Emperra GmbH E-Health Technologies
  • Eli Lilly and Company
  • Ypsomed Ag
  • Sanofi
  • Biocon
Note: Product cover images may vary from those shown